Positron emission tomography in cardiac amyloidosis: current evidence and future directions
Authors:
Open Access
- 10 February 2025
- journal article
- review article
- Published by Springer Nature in Heart Failure Reviews
- Vol. 30 (3) , 605-618
Abstract
The increasing recognition of cardiac amyloidosis (CA) as a cause of heart failure, coupled with advancements in therapeutic options, has underscored the need for early detection. Positron emission tomography (PET) imaging emerged as a promising non-invasive tool for diagnosing and managing CA. This review provides a comprehensive analysis of current PET imaging techniques, focusing on radiotracers, including [11C]Pittsburgh Compound B, [18F]Flutemetamol, [18F]Florbetapir, [18F]Florbetaben, [18F]-sodium fluoride, and [124I]Evuzamitide. PET imaging’s ability to differentiating CA subtypes and quantify amyloid burden contributes defining prognosis and aids in monitoring treatment response. However, standardizing imaging protocols and establishing definitive diagnostic thresholds remain challenging. As PET imaging continues to evolve, it promises to improve patient outcomes by facilitating earlier diagnosis, more accurate subtype differentiation, and better treatment monitoring in CA.Keywords
Funding Information
- Scuola Superiore Sant'Anna
This publication has 68 references indexed in Scilit:
- Deep-learning-based cardiac amyloidosis classification from early acquired pet imagesThe International Journal of Cardiovascular Imaging, 2021
- Advances in PET-Based Cardiac Amyloid RadiotracersCurrent Cardiology Reports, 2020
- Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiBEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)Cochrane Database of Systematic Reviews, 2017
- Imaging β-amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomographyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Use of Florbetapir-PET for Imaging β-Amyloid PathologyJAMA, 2011
- 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trialAnnals of Neurology, 2010
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004